Rodent pharmacokinetics and receptor occupancy of the GABAA receptor subtype selective benzodiazepine site ligand L‐838417
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The pharmacokinetics of L‐838417, a GABA A receptor subtype selective benzodiazepine site agonist, were studied in rats and mice after single oral (p.o.), intraperitoneal (i.p.) and intravenous (i.v.) doses. In both species L‐838417 was well absorbed following i.p. administration and whilst in rats p.o. bioavailability was good (41%), in mice it was negligible (<1%), precluding this as a route of administration for mouse behavioural studies. Despite having a similar volume of distribution (ca 1.4 l/kg) in rats and mice, L‐838417 was cleared at twice liver blood flow in mice (161 ml/min/kg) and moderately cleared in rats (24 ml/min/kg), potentially explaining the poor oral bioavailability in mice. Finally, as a pharmacodynamic readout the benzodiazepine binding site occupancy was determined in rats (0.3–3 mg/kg, p.o.) and mice (1–30 mg/kg, i.p.) using a [3 H]Ro 15‐1788 in vivo binding assay. Although the resulting dose‐occupancy relationship for both species demonstrated a dose‐dependent increase in receptor occupancy, appreciable variability was observed at low dose levels, potentially making interpretation of behavioural responses difficult. In contrast, a clear relationship between plasma and brain concentrations and receptor occupancy were determined suggesting the observed dose‐occupancy variability is a consequence of the pharmacokinetic properties of L‐838417. The plasma and brain concentrations required to occupy 50% of the benzodiazepine binding sites were similar in both rats (28 ng/ml and 33 ng/mlg, respectively) and mice (63 ng/ml and 53 ng/mlg, respectively), with a non‐linear concentration response observed with increasing doses of L‐838417. These studies demonstrate the importance of utilizing pharmacokinetic/receptor occupancy data when interpreting pharmacodynamic responses at a given dose. Copyright © 2004 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular and neuronal substrate for the selective attenuation of anxiety
Löw, K., Crestani, F., Keist, R., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Rülicke, T., Bluethmann, H., Möhler, H., et al. (2000) · Science · doi:10.1126/science.290.5489.131 · Cited by 946
McKernan, R. M., Rosahl, T. W., Reynolds, D. S., Sur, C., Wafford, K. A., Atack, J. R., Farrar, S., Myers, J., Cook, G., Ferris, P., et al. (2000) · Nature Neuroscience · doi:10.1038/75761 · Cited by 944
Self-citationA new benzodiazepine pharmacology
Möhler, H., Fritschy, J. M., & Rudolph, U. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.1.2 · Cited by 716 · cited 1×
“Ultimately, a better understanding of the specific functions of particular GABAA receptor subtypes should allow the development of new GABAA receptor subtype selective benzodiazepine site ligands with specific pharmacological actions and reduced side effect profiles [10].”
Collinson, N., Kuenzi, F. M., Jarolimek, W., Maubach, K. A., Cothliff, R., Sur, C., Smith, A., Otu, F. M., Howell, O., Atack, J. R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-13-05572.2002 · Cited by 628
Self-citationAnxiolytic effects of buspirone and gepirone in the fear-potentiated startle paradigm
Kehne, J. H., Cassella, J. V., & Davis, M. (1988) · Psychopharmacology · doi:10.1007/bf00735872 · Cited by 93
Cited by
Applications of Deuterium in Medicinal Chemistry
Pirali, T., Serafini, M., Cargnin, S., & Genazzani, A. A. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01808 · Cited by 855
Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes
Rudolph, U., & Knoflach, F. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3502 · Cited by 733
“However, unfavourable pharmacokinetic properties have precluded further development of this compoun”
BackgroundAlavijeh, M. S., Chishty, M., Qaiser, M. Z., & Palmer, A. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.4.554 · Cited by 497
Reversal of pathological pain through specific spinal GABAA receptor subtypes
Knabl, J., Witschi, R., Hösl, K., Reinold, H., Zeilhofer, U. B., Ahmadi, S., Brockhaus, J., Sergejeva, M., Hess, A., Brune, K., et al. (2008) · Nature · doi:10.1038/nature06493 · Cited by 438
Hooked on benzodiazepines: GABAA receptor subtypes and addiction
Tan, K. R., Rudolph, U., & Lüscher, C. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2011.01.004 · Cited by 365
Metadata
- Authors
- Scott‐Stevens, P., Atack, J. R., Sohal, B., & Worboys, P.
- Venue
- Biopharmaceutics & Drug Disposition
- Publisher
- Wiley
- Published
- 2004-12
- Volume
- 26
- Issue
- 1
- Pages
- 13-20
- ISSN
- 0142-2782 (ISSN-L)
- 1099-081X
- OpenAlex
- W2157050914
- Cited by
- 50
- References
- 5
- FWCI
- 0.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.